RGD-HSA-TAC nanoparticles targeted delivery of tacrolimus and attenuation of podocyte injury in diabetic kidney disease
Abstract Background Diabetic kidney disease (DKD) is a prevalent and severe complication of diabetes and plays a pivotal role in the pathogenesis and progression of DKD. However, the current clinical application of the treatment methods does not yield effective results. Tacrolimus has been utilized...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Journal of Nanobiotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12951-025-03108-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823861619071909888 |
|---|---|
| author | Zhaochen Guo Shaohui Gao Feng Xu Zige Chen Qinger Wang Zhaojie Liu Ziyue Wang Weisong Qin Caihong Zeng Zhihong Liu Hao Bao |
| author_facet | Zhaochen Guo Shaohui Gao Feng Xu Zige Chen Qinger Wang Zhaojie Liu Ziyue Wang Weisong Qin Caihong Zeng Zhihong Liu Hao Bao |
| author_sort | Zhaochen Guo |
| collection | DOAJ |
| description | Abstract Background Diabetic kidney disease (DKD) is a prevalent and severe complication of diabetes and plays a pivotal role in the pathogenesis and progression of DKD. However, the current clinical application of the treatment methods does not yield effective results. Tacrolimus has been utilized in the management of immune-mediated and genetic-mediated nephropathy, with an emphasis on the restoration of podocyte cytoskeletal integrity and inhibition of apoptosis. The clinical management of diabetic nephropathy with tacrolimus remains challenging because of the risk of worsening hyperglycemia and infection. Results We developed two RGD-HSA-TAC nanoparticles designed for targeted delivery of tacrolimus to podocytes. Administration of SANPs and CNPs resulted in elevated levels of tacrolimus in podocytes, leading to a reduction in podocyte damage and albuminuria in diabetic nephropathy mice. Furthermore, the use of SANPs and CNPs resulted in a decrease in tacrolimus accumulation in the pancreas, lymph nodes, and thymus, thereby reducing the potential to exacerbate hyperglycemia and infection. Importantly, compared to tacrolimus alone, both SANPs and CNPs demonstrated superior therapeutic efficacy, with CNPs exhibiting a greater advantage over SANPs. Conclusions Compared to tacrolimus, SANPs and CNPs demonstrated superior therapeutic efficacy and a reduced incidence of adverse effects in the treatment of diabetic nephropathy. Graphical abstract |
| format | Article |
| id | doaj-art-17163b41080a4345a037c10350e2afc4 |
| institution | Kabale University |
| issn | 1477-3155 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Nanobiotechnology |
| spelling | doaj-art-17163b41080a4345a037c10350e2afc42025-02-09T12:52:56ZengBMCJournal of Nanobiotechnology1477-31552025-02-0123112010.1186/s12951-025-03108-4RGD-HSA-TAC nanoparticles targeted delivery of tacrolimus and attenuation of podocyte injury in diabetic kidney diseaseZhaochen Guo0Shaohui Gao1Feng Xu2Zige Chen3Qinger Wang4Zhaojie Liu5Ziyue Wang6Weisong Qin7Caihong Zeng8Zhihong Liu9Hao Bao10National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNational Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Urology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNational Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNational Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNational Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNational Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNational Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNational Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNational Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNational Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityAbstract Background Diabetic kidney disease (DKD) is a prevalent and severe complication of diabetes and plays a pivotal role in the pathogenesis and progression of DKD. However, the current clinical application of the treatment methods does not yield effective results. Tacrolimus has been utilized in the management of immune-mediated and genetic-mediated nephropathy, with an emphasis on the restoration of podocyte cytoskeletal integrity and inhibition of apoptosis. The clinical management of diabetic nephropathy with tacrolimus remains challenging because of the risk of worsening hyperglycemia and infection. Results We developed two RGD-HSA-TAC nanoparticles designed for targeted delivery of tacrolimus to podocytes. Administration of SANPs and CNPs resulted in elevated levels of tacrolimus in podocytes, leading to a reduction in podocyte damage and albuminuria in diabetic nephropathy mice. Furthermore, the use of SANPs and CNPs resulted in a decrease in tacrolimus accumulation in the pancreas, lymph nodes, and thymus, thereby reducing the potential to exacerbate hyperglycemia and infection. Importantly, compared to tacrolimus alone, both SANPs and CNPs demonstrated superior therapeutic efficacy, with CNPs exhibiting a greater advantage over SANPs. Conclusions Compared to tacrolimus, SANPs and CNPs demonstrated superior therapeutic efficacy and a reduced incidence of adverse effects in the treatment of diabetic nephropathy. Graphical abstracthttps://doi.org/10.1186/s12951-025-03108-4Diabetic kidney diseaseTargeted deliveryNanoparticleHSATacrolimus |
| spellingShingle | Zhaochen Guo Shaohui Gao Feng Xu Zige Chen Qinger Wang Zhaojie Liu Ziyue Wang Weisong Qin Caihong Zeng Zhihong Liu Hao Bao RGD-HSA-TAC nanoparticles targeted delivery of tacrolimus and attenuation of podocyte injury in diabetic kidney disease Journal of Nanobiotechnology Diabetic kidney disease Targeted delivery Nanoparticle HSA Tacrolimus |
| title | RGD-HSA-TAC nanoparticles targeted delivery of tacrolimus and attenuation of podocyte injury in diabetic kidney disease |
| title_full | RGD-HSA-TAC nanoparticles targeted delivery of tacrolimus and attenuation of podocyte injury in diabetic kidney disease |
| title_fullStr | RGD-HSA-TAC nanoparticles targeted delivery of tacrolimus and attenuation of podocyte injury in diabetic kidney disease |
| title_full_unstemmed | RGD-HSA-TAC nanoparticles targeted delivery of tacrolimus and attenuation of podocyte injury in diabetic kidney disease |
| title_short | RGD-HSA-TAC nanoparticles targeted delivery of tacrolimus and attenuation of podocyte injury in diabetic kidney disease |
| title_sort | rgd hsa tac nanoparticles targeted delivery of tacrolimus and attenuation of podocyte injury in diabetic kidney disease |
| topic | Diabetic kidney disease Targeted delivery Nanoparticle HSA Tacrolimus |
| url | https://doi.org/10.1186/s12951-025-03108-4 |
| work_keys_str_mv | AT zhaochenguo rgdhsatacnanoparticlestargeteddeliveryoftacrolimusandattenuationofpodocyteinjuryindiabetickidneydisease AT shaohuigao rgdhsatacnanoparticlestargeteddeliveryoftacrolimusandattenuationofpodocyteinjuryindiabetickidneydisease AT fengxu rgdhsatacnanoparticlestargeteddeliveryoftacrolimusandattenuationofpodocyteinjuryindiabetickidneydisease AT zigechen rgdhsatacnanoparticlestargeteddeliveryoftacrolimusandattenuationofpodocyteinjuryindiabetickidneydisease AT qingerwang rgdhsatacnanoparticlestargeteddeliveryoftacrolimusandattenuationofpodocyteinjuryindiabetickidneydisease AT zhaojieliu rgdhsatacnanoparticlestargeteddeliveryoftacrolimusandattenuationofpodocyteinjuryindiabetickidneydisease AT ziyuewang rgdhsatacnanoparticlestargeteddeliveryoftacrolimusandattenuationofpodocyteinjuryindiabetickidneydisease AT weisongqin rgdhsatacnanoparticlestargeteddeliveryoftacrolimusandattenuationofpodocyteinjuryindiabetickidneydisease AT caihongzeng rgdhsatacnanoparticlestargeteddeliveryoftacrolimusandattenuationofpodocyteinjuryindiabetickidneydisease AT zhihongliu rgdhsatacnanoparticlestargeteddeliveryoftacrolimusandattenuationofpodocyteinjuryindiabetickidneydisease AT haobao rgdhsatacnanoparticlestargeteddeliveryoftacrolimusandattenuationofpodocyteinjuryindiabetickidneydisease |